Los puntos clave no están disponibles para este artículo en este momento.
The impact of remdesivir on mortality in patients with COVID-19 is still controversial. We aimed to identify clinical phenotype clusters of COVID-19 hospitalized patients with highest benefit from remdesivir use and validate these findings in an external cohort.
García‐Vidal et al. (Fri,) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: